Abstract
Microscopic colitis is a common cause of chronic watery diarrhea with a great impact on patient quality of life. Microscopic colitis includes two histological subtypes: collagenous colitis and lymphocytic colitis. Due to the increasing incidence and awareness of this disease over the last decades, several international guidelines have been recently published. However, there is still significant heterogeneity in the management of these patients, and treatments without solid scientific evidence support are often used in clinical practice. This article reviews the therapeutic role of budesonide in microscopic colitis and summarizes the current evidence regarding other treatments available for this disease, especially for the management of refractory patients. Finally, an updated treatment algorithm is proposed.
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Anti-Inflammatory Agents / adverse effects
-
Anti-Inflammatory Agents / metabolism
-
Anti-Inflammatory Agents / therapeutic use*
-
Antidiarrheals / therapeutic use
-
Antimetabolites / therapeutic use
-
Azathioprine / therapeutic use
-
Biological Products / adverse effects
-
Biological Products / therapeutic use
-
Budesonide / adverse effects
-
Budesonide / metabolism
-
Budesonide / therapeutic use*
-
Colitis, Collagenous / drug therapy*
-
Colitis, Collagenous / pathology
-
Colitis, Lymphocytic / drug therapy*
-
Colitis, Lymphocytic / pathology
-
Colitis, Microscopic / drug therapy
-
Colitis, Microscopic / pathology
-
Diarrhea / etiology
-
Humans
-
Loperamide / therapeutic use
-
Malabsorption Syndromes / drug therapy
-
Mesalamine / therapeutic use
-
Methotrexate / therapeutic use
-
Prednisolone / therapeutic use
-
Quality of Life
-
Randomized Controlled Trials as Topic
-
Recurrence
-
Remission Induction
-
Time Factors
Substances
-
Adrenal Cortex Hormones
-
Anti-Inflammatory Agents
-
Antidiarrheals
-
Antimetabolites
-
Biological Products
-
Mesalamine
-
Budesonide
-
Loperamide
-
Prednisolone
-
Azathioprine
-
Methotrexate